Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759873 | 1.00 | ALOX15 (0.47) | ALOX15P2RY12MGLLROCK2HPGD | |
| SCHEMBL22910576 | 0.90 | MGLL (0.36) | ALOX15P2RY12MGLLROCK2HPGD | |
| SCHEMBL16759893 | 0.90 | MGLL (0.36) | ALOX15P2RY12MGLLROCK2HPGD | |
| SCHEMBL16759905 | 0.90 | MGLL (0.43) | ALOX15P2RY12MGLLKMT2A | |
| SCHEMBL22911093 | 0.90 | MGLL (0.43) | ALOX15P2RY12MGLLKMT2A | |
| SCHEMBL22910814 | 0.90 | P2RY12 (0.39) | ALOX15P2RY12MGLLROCK2HPGD | |
| SCHEMBL16759842 | 0.90 | P2RY12 (0.39) | ALOX15P2RY12MGLLROCK2HPGD | |
| SCHEMBL16759841 | 0.89 | ALDH1A1 (0.44) | MGLLHPGD | |
| SCHEMBL22910580 | 0.89 | ALDH1A1 (0.44) | MGLLHPGD | |
| SCHEMBL16759723 | 0.88 | ROCK2 (0.42) | MGLLROCK2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | ALOX15 1905/4885P2RY12 2685/4885MGLL 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.